|
1
|
Abdelhamed S, Butler JT, Jung S, Chen DW, Jenkins G, Gao L, Lim JY, Klco JM, Horton TM, Kurre P. Rational biomarker development for the early and minimally invasive monitoring of AML. Blood Adv 2021; 5:4515-4520. [PMID: 34587228 PMCID: PMC8579272 DOI: 10.1182/bloodadvances.2021004621] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2021] [Accepted: 08/08/2021] [Indexed: 12/18/2022] Open
Abstract
Recurrent disease remains the principal cause for treatment failure in acute myeloid leukemia (AML) across age groups. Reliable biomarkers of AML relapse risk and disease burden have been problematic, as symptoms appear late and current monitoring relies on invasive and cost-ineffective serial bone marrow (BM) surveillance. In this report, we discover a set of unique microRNA (miRNA) that circulates in AML-derived vesicles in the peripheral blood ahead of the general dissemination of leukemic blasts and symptomatic BM failure. Next-generation sequencing of extracellular vesicle-contained small RNA in 12 AML patients and 12 controls allowed us to identify a panel of differentially incorporated miRNA. Proof-of-concept studies using a murine model and patient-derived xenografts demonstrate the feasibility of developing miR-1246, as a potential minimally invasive AML biomarker.
Collapse
Affiliation(s)
- Sherif Abdelhamed
- Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN
| | - John T. Butler
- Department of Pediatrics, Pape Family Pediatric Research Institute, OHSU, Portland, OR
- Department of Biomedical Engineering, OHSU, Portland, OR
| | - Seul Jung
- Children’s Hospital of Philadelphia, Comprehensive Bone Marrow Failure Center, Philadelphia, PA
| | - Ding-Wen Chen
- Children’s Hospital of Philadelphia, Comprehensive Bone Marrow Failure Center, Philadelphia, PA
| | - Gaye Jenkins
- Baylor College of Medicine/Dan L. Duncan Cancer Center
- Texas Children's Cancer Center, Houston, TX
| | - Lina Gao
- Biostatistics Shared Resource, Knight Cancer Institute, OHSU, Portland, OR; and
| | - Jeong Y. Lim
- Biostatistics Shared Resource, Knight Cancer Institute, OHSU, Portland, OR; and
| | - Jeffery M. Klco
- Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN
| | - Terzah M. Horton
- Baylor College of Medicine/Dan L. Duncan Cancer Center
- Texas Children's Cancer Center, Houston, TX
| | - Peter Kurre
- Children’s Hospital of Philadelphia, Comprehensive Bone Marrow Failure Center, Philadelphia, PA
- University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
| |
Collapse
|
|
2
|
de Carvalho INSR, de Freitas RM, Vargas FR. Translating microRNAs into biomarkers: What is new for pediatric cancer? Med Oncol 2016; 33:49. [DOI: 10.1007/s12032-016-0766-4] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Accepted: 04/11/2016] [Indexed: 02/06/2023]
|